The successful Phase 3 trial results for obicetrapib, showing significant reductions in LDL-C and Lp(a) levels, are likely to positively impact NewAmsterdam Pharma's stock price. The drug's safety profile being comparable to placebo further strengthens its potential marketability, making it a promising candidate for patients with HeFH. This news is highly relevant and important for investors as it could lead to increased market share and revenue for the company.